Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Amivantamab and hyaluronidase-lpuj injection - Janssen Biotech

Next Previous
Drug Profile

Amivantamab and hyaluronidase-lpuj injection - Janssen Biotech

Alternative Names: Ami-HC-CF; Ami-LC-MD; Amivantamab admixed with rHuPH20; amivantamab and hyaluronidase-lpuj; amivantamab+hyaluronidase-lpuj; RYBREVANT FASPRO; RYBROFAZ; RybrofazTN

Latest Information Update: 24 Feb 2026

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Janssen Biotech
  • Developer Halozyme Therapeutics; Janssen Biotech
  • Class Antineoplastics; Bispecific antibodies; Glycoside hydrolases; Immunotherapies; Polysaccharide lyases
  • Mechanism of Action Antibody-dependent cell cytotoxicity
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Marketed Non-small cell lung cancer
  • Phase I Solid tumours

Most Recent Events

  • 18 Feb 2026 Amivantamab and hyaluronidase-lpuj injection - Janssen Biotech receives Breakthrough Therapy status for Squamous cell cancer (Recurrent, Metastatic disease, Second-line therapy or greater) in USA
  • 17 Feb 2026 Registered for Non-small cell lung cancer (First-line therapy, Late-stage disease) in China (SC)
  • 17 Dec 2025 Registered for Non-small cell lung cancer (First-line therapy, Late-stage disease) in Japan (SC)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top